Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect®CLL cohort study
Year: 2018
Type: article
Abstract: CLL registry, a prospective observational cohort study of 1494 patients treated in 199 US centers, median time to first-line treatment initiation was 3.8, 1.5, and 0.6 years for patients with Rai stage 0, 1, and ≥2, respectively. Only 60% of patients with Rai stage 0/1 underwent FISH/cytogenetic testing prior to initiation of a new line of therapy. Lymphocytosis and lymphadenopathy were the most common reasons for treatment initiation. Lymphocytosis as a reason for treatment initiation was associated with inferior event-free survival at Rai stage 0/1. Short treatment duration was associated with inferior overall survival regardless of Rai stage; sensitivity analyses confirmed the association. The Connect CLL registry provides valuable information on a real-world population of patients with CLL, clarifying both the timing and rationale for initiating therapy.
Institutions: Emory University, Winship Cancer Institute, Cardinal Health (United States), Mayo Clinic, Abramson Cancer Center, University of Pennsylvania, NewYork–Presbyterian Hospital, Columbia University Irving Medical Center, Summit Medical Group (United States), Dana-Farber Cancer Institute, Celgene (United States), Willamette Valley Cancer Institute and Research Center
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Celgene
OpenAlex ID: W2790376386